| 施亚楠,郭勇.健脾类中药联合化疗治疗晚期非小细胞肺癌的meta分析[J].浙江中西医结合杂志,2025,35(11): |
| 健脾类中药联合化疗治疗晚期非小细胞肺癌的meta分析 |
| Meta-analysis of spleen-strengthening Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer |
| 投稿时间：2024-07-20 修订日期：2025-06-10 |
| DOI： |
| 中文关键词: 非小细胞肺癌 健脾 中药 化疗 Meta 分析 |
| 英文关键词:Non-small cell lung cancer Tonifying spleen Traditional Chinese medicine chemotherapy meta-analysis |
| 基金项目: |
|
| 摘要点击次数: 65 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘要：目的 运用Meta分析的方式对健脾类中药联合化疗治疗晚期NSCLC的疗效及安全性进行评价。方法 由2位研究员通过计算机检索知网、万方、维普、Sinomed、Pubmed、Embase、Cochrane Library等数据库，收集健脾类中药联合含铂化疗治疗晚期NSCLC的随机对照试验，筛选文献，提取数据，采用Stata14.0或Stata16.0、Revman5.3软件进行统计分析。结果 最后纳入41个RCT，Meta分析结果显示，在疾病控制率上，健脾类中药联合含铂化疗优于单纯含铂化疗[RR=1.16，95%CI（1.12，1.20），P＜0.05]；在生活质量上，健脾类中药联合含铂化疗较单纯含铂化疗有所改善[RR=1.41，95%CI（1.27，1.56），P＜0.05]；在不良反应发生率上，健脾类中药联合含铂化疗较单纯含铂化疗明显降低[白细胞减少率RR=0.67，95%CI（0.59，0.75），P＜0.05][血红蛋白减少发生率RR=0.61，95%CI（0.53，0.71），P＜0.05][血小板减少发生率RR=0.62，95%CI（0.53，0.72），P＜0.05][消化道反应发生率RR=0.63，95%CI（0.54，0.73）,（Z=6.02，P＜0.00001＜0.05]；在免疫功能上，健脾类中药联合含铂化疗比单纯含铂化疗更能改善患者的免疫功能[CD3+ MD=8.32,95%CI（4.97，11.66）,P＜0.05）][CD4+ MD=7.15,95%CI（6.05，8.26）,P＜0.05][CD8+ MD=-4.19,95%CI（-5.49，-2.89）,P＜0.05][CD4+/CD8+ MD=0.38,95%CI（0.28，0.47）,P＜0.05]。结论 健脾类中药联合含铂化疗较单纯含铂化疗更能改善NSCLC患者的生活质量，健脾类中药联合含铂化疗的疾病控制率更好，健脾类中药联合含铂化疗更能降低不良反应（消化道反应、血液毒性）发生率，健脾类中药联合含铂化疗能改善免疫功能。 |
| 英文摘要: |
| Abstract: Objective To evaluate the efficacy and safety of herbal medicine for tonifying the spleen combined with chemotherapy in treating advanced NSCLC using a meta-analysis. Methods Two researchers searched computer databases, including CNKI, Wanfang, VIP, Sinomed, Pubmed, Embase, and the Cochrane Library, for randomized controlled trials (RCTs) of herbal medicine for tonifying the spleen combined with platinum-based chemotherapy for advanced NSCLC. The literature was screened and data were extracted. The analysis was conducted using Stata 14.0 or 16.0 and Revman 5.3 software. Results A total of 41 RCTs were finally included in the meta-analysis. The results showed that the disease control rate was better with herbal medicine for tonifying the spleen combined with platinum-based chemotherapy than with platinum-based chemotherapy alone[RR=1.16，95%CI（1.12，1.20），P＜0.05]. The quality of life was improved with herbal medicine for tonifying the spleen combined with platinum-based chemotherapy compared with platinum-based chemotherapy alone[RR=1.41，95%CI（1.27，1.56），P＜0.05]. The incidence of adverse reactions was significantly lower with herbal medicine for tonifying the spleen combined with platinum-based chemotherapy than with platinum-based chemotherapy alone[白细胞减少率RR=0.67，95%CI（0.59，0.75），P＜0.05][血红蛋白减少发生率RR=0.61，95%CI（0.53，0.71），P＜0.05][血小板减少发生率RR=0.62，95%CI（0.53，0.72），P＜0.05][消化道反应发生率RR=0.63，95%CI（0.54，0.73）,（Z=6.02，P＜0.00001＜0.05]. The immune function was improved with herbal medicine for tonifying the spleen combined with platinum-based chemotherapy compared with platinum-based chemotherapy alone[CD3+ MD=8.32,95%CI（4.97，11.66）,P＜0.05）][CD4+ MD=7.15,95%CI（6.05，8.26）,P＜0.05][CD8+ MD=-4.19,95%CI（-5.49，-2.89）,P＜0.05][CD4+/CD8+ MD=0.38,95%CI（0.28，0.47）,P＜0.05]. Conclusion Herbal medicine for tonifying the spleen combined with platinum-based chemotherapy is better at improving the quality of life of patients with advanced NSCLC, has a better disease control rate, reduces the incidence of adverse reactions (digestive tract reactions and hematotoxicity), and improves immune function compared with platinum-based chemotherapy alone. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
